Statistical correlations between peripheral blood lymphocyte subpopulations and tumor inflammatory infiltrate in stage I of skin melanoma

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 4, 2010, Pages 693-699

  Costache, Mariana ^a,b   Neagu, Monica ^b   Petrescu, Angela ^b   Constantin, Carolina ^b   Manda, Gina ^b   Vrabie, Camelia Doina ^a,b,c   Waller, Maria ^b   Petrescu, C S ^b   Simionescu, Olga ^a,d  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^c 'Sf Ioan' Hospital   (Romania)

^d V Babes National Institute of Pathology   (Romania)

Author keywords

CD4+; CD8+; Immunotherapy; Melanoma; Stage 1; Statistics; T cell

Indexed keywords

LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTICLE; BIOSTATISTICS; BLOOD; CANCER STAGING; HUMAN; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD; BIOSTATISTICS; HUMANS; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 78649952438     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. CHIN L, GARRAWAY LA, FISHER DE, Malignant melanoma: genetics and therapeutics in the genomic era, Genes Dev, 2006, 20(16):2149-2182.
2. TAS F, OGUZ H, ARGON A, DURANYILDIZ D, CAMLICA H, YASASEVER V, TOPUZ E, The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma, Med Oncol, 2005, 22(3):241-246.
3. NEAGU M, CONSTANTIN C, MANDA G, MARGARITESCU I, Biomarkers of metastatic melanoma, Biomark Med, 2009, 3(1):71-89.
4. JEMAL A, CLEGG LX, WARD E, RIES LA, WU X, JAMISON PM, WINGO PA, HOWE HL, ANDERSON RN, EDWARDS BK, Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival, Cancer, 2004, 101(1):3-27.
5. BALCH CM, Cutaneous melanoma: prognosis and treatment results worldwide, Semin Surg Oncol, 1992, 8(6):400-414.
6. VENCE L, PALUCKA AK, FAY JW, ITO T, LIU YJ, BANCHEREAU J, UENO H, Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma, Proc Natl Acad Sci U S A, 2007, 104(52):20884-20889.
7. GAJEWSKI TF, Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment, Clin Cancer Res, 2006, 12(7 Pt 2):2326s-2330s.
8. GERLINI G, MARIOTTI G, CHIARUGI A, DI GENNARO P, CAPORALE R, PARENTI A, CAVONE L, TUN-KYI A, PRIGNANO F, SACCARDI R, BORGOGNONI L, PIMPINELLI N, Induction of CD83+CD14+ nondendritic antigen-presenting cells by exposure of monocytes to IFN-alpha, J Immunol, 2008, 181(5):2999-3008.
9. YURKOVETSKY ZR, KIRKWOOD JM, EDINGTON HD, MARRANGONI AM, VELIKOKHATNAYA L, WINANS MT, GORELIK E, LOKSHIN AE, Multiplex analysis of serum cytokines in melanoma patients treated with interferonalpha2b, Clin Cancer Res, 2007, 13(8):2422-2428.
10. MOELLMANN G, MCGUIRE J, LERNER AB, Ultrastructure and cell biology of pigment cells. Intracellular dynamics and the fine structure of melanocytes with special reference to the effects of MSH and cyclic AMP on microtubules and 10-nm filaments, Yale J Biol Med, 1973, 46(5):337-360.
11. REZAUL K, WILSON LL, HAN DK, Direct tissue proteomics in human diseases: potential applications to melanoma research, Expert Rev Proteomics, 2008, 5(3):405-412.
12. BOLTON S, Pharmaceutical statistics: practical and clinical applications, 2nd edition, Drugs and the Pharmaceutical Sciences, vol. 44, Marcel Dekker, New York, 1990.
13. PREDA V, Teoria deciziilor statistice, Ed. Academiei Române, Bucureşti, 1992.
14. JABA E, GRAMA A, Analiza statisticǎ cu SPSS sub Windows, Ed. Polirom, Iaşi, 2004.
15. KAWAKAMI K, KADOTA J, IIDA K, SHIRAI R, ABE K, KOHNO S, Reduced immune function and malnutrition in the elderly, Tohoku J Exp Med, 1999, 187(2):157-171.
16. JABA E, Statistica, ediţia a 3-a, Ed. Economicǎ, Bucureşti, 2002.
17. BALCH CM, MURAD TM, SOONG SJ, INGALLS AL, HALPERN NB, MADDOX WA, A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods, Ann Surg, 1978, 188(6):732-742.
18. BALCH CM, SOONG SJ, SHAW HM, MILTON GW, An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: BALCH CM, MILTON GW (eds), Cutaneous melanoma: clinical management and treatment results worldwide, J.B. Lippincott, Philadelphia, 1985, 321-352.
19. SIMIONESCU O, DUMITRESCU D, COSTACHE M, BLUM A, Dermatoscopy of an invasive melanoma on the upper lip shows possible association with Laugier-Hunziker syndrome, J Am Acad Dermatol, 2008, 59(5 Suppl):S105-S108.
20. SØNDERGAARD K, SCHOU G, Therapeutic and clinicopathological factors in survival of 1,469 patients with primary cutaneous malignant melanoma in clinical stage I. A multivariate regression analysis, Virchows Arch A Pathol Anat Histopathol, 1985, 408(2-3):249-258.
21. WEISSMANN A, ROSES DF, HARRIS MN, DUBIN N, Prediction of lymph node metastases from the histologic features of primary cutaneous malignant melanomas, Am J Dermatopathol, 1984, 6 Suppl:35-41.
22. MASCARO JM, MOLGO M, CASTEL T, CASTRO J, Plasma cells within the infiltrate of primary cutaneous malignant melanoma of the skin. A confirmation of its histoprognostic value, Am J Dermatopathol, 1987, 9(6):497-499.
23. DRÉAU D, FOSTER M, HOGG M, SWIGGETT J, HOLDER WD, WHITE RL, Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma, Oncol Res, 2000, 12(5):241-251.
24. SHAH KV, CHIEN AJ, YEE C, MOON RT, CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors, J Invest Dermatol, 2008, 128(12):2870-2879.
25. SLINGLUFF CL JR, PETRONI GR, OLSON W, CZARKOWSKI A, GROSH WW, SMOLKIN M, CHIANESE-BULLOCK KA, NEESE PY, DEACON DH, NAIL C, MERRILL P, FINK R, PATTERSON JW, REHM PK, Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens, J Clin Oncol, 2008, 26(30):4973-4980.
26. VIHINEN PP, HILLI J, VUORISTO MS, SYRJÄNEN KJ, KÄHÄRI VM, PYRHÖNEN SO, Serum VEGF-C is associated with metastatic site in patients with malignant melanoma, Acta Oncol, 2007, 46(5):678-684.
27. GRIZZI F, CHIRIVA-INTERNATI M, Cancer: looking for simplicity and finding complexity, Cancer Cell Int, 2006, 6:4-10.